Insight Molecular Diagnostics (IMDX) Return on Capital Employed (2016 - 2026)
Insight Molecular Diagnostics (IMDX) posted Return on Capital Employed of 38.7% for Q1 2026, up 16.44% sequentially from 46.32% in Q4 2025, and down 1170.0% YoY from 3.62% in Q1 2025.
Insight Molecular Diagnostics (IMDX) Return on Capital Employed (2016 - 2026) Analysis & Trends
Insight Molecular Diagnostics (IMDX) has 11 years of Return on Capital Employed data on file, last reported at 38.7% in Q1 2026.
- Quarterly Return on Capital Employed fell 1170.0% year-over-year to 38.7% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 38.7% (down 1170.0% YoY) and the FY2025 annual result came in at 57.5%, down 3080.0% from the prior year.
- Return on Capital Employed grew to 38.7% in Q1 2026 per IMDX's latest filing, from 46.32% in the prior quarter.
- The five-year high for Return on Capital Employed was 11.13% in Q1 2023, with the low at 68.78% in Q3 2024.
- Average Return on Capital Employed over 5 years is 36.08%, with a median of 32.89% recorded in 2025.
- Year-over-year, Return on Capital Employed soared 3627 bps in 2023 and sank 5117 bps in 2024.
- Insight Molecular Diagnostics' Return on Capital Employed stood at 15.43% in 2022, then sank by 129 bps to 35.38% in 2023, then rose by 21 bps to 28.08% in 2024, then plunged by 65 bps to 46.32% in 2025, then rose by 16 bps to 38.7% in 2026.
- Business Quant data shows IMDX's Return on Capital Employed at 38.7% in Q1 2026, 46.32% in Q4 2025, and 32.89% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Waters | 31,055.11 Bn | 31,054.65 Bn | 1.11 Bn | 4.82% |
| 2 | Thermo Fisher Scientific | 191.02 Bn | 187.77 Bn | 7.74 Bn | 8.12% |
| 3 | Danaher | 137.16 Bn | 131.47 Bn | 3.59 Bn | 6.26% |
| 4 | Idexx Laboratories | 42.82 Bn | 42.62 Bn | 722.74 Mn | 67.98% |
| 5 | Natera | 39.09 Bn | 37.99 Bn | 696.04 Mn | -3.63% |
| 6 | Agilent Technologies | 37.61 Bn | 35.81 Bn | 990.00 Mn | 14.57% |
| 7 | Iqvia Holdings | 34.23 Bn | 32.25 Bn | 1.36 Bn | 10.24% |
| 8 | Illumina | 28.14 Bn | 26.98 Bn | 721.00 Mn | 16.90% |
| 9 | Mettler Toledo International | 26.40 Bn | 26.33 Bn | 555.82 Mn | 45.73% |
| 10 | Insight Molecular Diagnostics | 196.41 Mn | 167.48 Mn | 15,000.00 | -38.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.70% |
| Dec 31, 2025 | -46.32% |
| Sep 30, 2025 | -32.89% |
| Jun 30, 2025 | -31.73% |
| Mar 31, 2025 | -27.00% |
| Dec 31, 2024 | -28.08% |
| Sep 30, 2024 | -68.78% |
| Jun 30, 2024 | -55.74% |
| Mar 31, 2024 | -62.31% |
| Dec 31, 2023 | -35.38% |
| Sep 30, 2023 | -26.92% |
| Jun 30, 2023 | -20.38% |
| Mar 31, 2023 | -11.13% |
| Dec 31, 2022 | -15.43% |
| Sep 30, 2022 | -27.79% |
| Jun 30, 2022 | -37.32% |
| Mar 31, 2022 | -47.40% |
| Dec 31, 2021 | -49.53% |
| Sep 30, 2021 | -28.09% |
| Jun 30, 2021 | -28.03% |